External broker reports(aggregated public sources), Wilsons Advisory

Wilsons Advisory

Wilsons has a distinguished history in financial services that spans over 125 years. Today, the group has significant capabilities in private wealth management, corporate finance, research and investment strategy, and institutional sales. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<ul><li>We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $3.12/sh (unrisked $7.71/sh).</li><li>Clarity have recently completed a $110M institutional equity placement and entitlement offer (with ongoing retail component) that will see them funded through to CY26 including major trial programs for their PSMA directed assets (64Cu/67Cu-SAR-bisPSMA) as they progress through Phase II &amp; Phase III.</li><li>Removal of funding overhang from the stock will be supportive of SP momentum given Clarity still have plenty of data yet to share this year with their SABRE trial, focused on non-PSMA avid prostate cancer diagnosis, the next big catalyst in the coming months. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $3.12/sh (unrisked $7.71/sh).Clarity have recently completed a $110M institutional equity placement and entitlement offer (with ongoing retail component) that will see them funded through to CY26 including major trial programs for their PSMA directed assets (64Cu/67Cu-SAR-bisPSMA) as they progress through Phase II &amp; Phase III.Removal of funding overhang from the stock will be supportive of SP momentum given Clarity still have plenty of data yet to share this year with their SABRE trial, focused on non-PSMA avid prostate cancer diagnosis, the next big catalyst in the coming months. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - Cash for Copper